Urologic oncology practice during COVID-19 pandemic: A systematic review on what can be deferrable vs. nondeferrable.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
10 2020
Historique:
received: 24 04 2020
revised: 20 06 2020
accepted: 21 06 2020
pubmed: 25 7 2020
medline: 26 9 2020
entrez: 25 7 2020
Statut: ppublish

Résumé

To provide a review of high-risk urologic cancers and the feasibility of delaying surgery without impacting oncologic or mortality outcomes. A thorough literature review was performed using PubMed and Google Scholar to identify articles pertaining to surgical delay and genitourinary oncology. We reviewed all relevant articles pertaining to kidney, upper tract urothelial cell, bladder, prostate, penile, and testicular cancer in regard to diagnostic, surgical, or treatment delay. The majority of urologic cancers rely on surgery as primary treatment. Treatment of unfavorable intermediate or high-risk prostate cancer, can likely be delayed for 3 to 6 months without affecting oncologic outcomes. Muscle-invasive bladder cancer and testicular cancer can be treated initially with chemotherapy. Surgical management of T3 renal masses, high-grade upper tract urothelial carcinoma, and penile cancer should not be delayed. The majority of urologic oncologic surgeries can be safely deferred without impacting long-term cancer specific or overall survival. Notable exceptions are muscle-invasive bladder cancer, high-grade upper tract urothelial cell, large renal masses, testicular and penile cancer. Joint decision making among providers and patients should be encouraged. Clinicians must manage emotional anxiety and stress when decisions around treatment delays are necessary as a result of a pandemic.

Identifiants

pubmed: 32703636
pii: S1078-1439(20)30297-0
doi: 10.1016/j.urolonc.2020.06.028
pmc: PMC7318929
pii:
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

783-792

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

J Urol. 1973 Sep;110(3):303-5
pubmed: 4725734
J Urol. 2003 Jan;169(1):110-5; discussion 115
pubmed: 12478115
J Urol. 2016 Apr;195(4 Pt 1):880-5
pubmed: 26598426
Urol Oncol. 2016 Apr;34(4):166.e1-6
pubmed: 26705102
J Urol. 1990 Mar;143(3):520-3
pubmed: 2304163
BJU Int. 2005 Oct;96(6):773-6
pubmed: 16153197
Crit Rev Oncol Hematol. 2019 Mar;135:59-65
pubmed: 30819447
Br J Urol. 1990 Jun;65(6):629-33
pubmed: 2164865
Eur Urol. 2008 Jul;54(1):161-8
pubmed: 18440124
Eur Urol. 2005 Jun;47(6):756-60
pubmed: 15925069
Eur Urol. 2013 Aug;64(2):204-15
pubmed: 23453419
Urol Oncol. 2019 Feb;37(2):116-122
pubmed: 30509868
Urology. 2016 Apr;90:e1-2
pubmed: 26772645
J Urol. 2017 Dec;198(6):1346-1352
pubmed: 28652123
Urol Int. 2014;92(4):455-61
pubmed: 24602994
Cancer. 2009 Mar 1;115(5):988-96
pubmed: 19142878
J Endourol. 2012 May;26(5):566-73
pubmed: 21879886
Eur Urol. 2020 Jun;77(6):663-666
pubmed: 32279903
Eur Urol. 2020 Jun;77(6):667-668
pubmed: 32312544
Urol Clin North Am. 1992 May;19(2):319-24
pubmed: 1574822
BJU Int. 2012 Jul;110(2):211-6
pubmed: 22093486
Urol Oncol. 2013 May;31(4):407-13
pubmed: 20884249
J Urol. 2009 Oct;182(4):1318-24
pubmed: 19683272
J Urol. 1972 Sep;108(3):428-30
pubmed: 5052252
EClinicalMedicine. 2020 Apr 05;21:100331
pubmed: 32292899
World J Urol. 2018 Aug;36(8):1225-1231
pubmed: 29549484
Eur Urol. 2020 Jun;77(6):713-724
pubmed: 32089359
Prostate. 2013 Mar;73(4):409-17
pubmed: 22996686
J Cancer Res Clin Oncol. 2012 Sep;138(9):1561-7
pubmed: 22547152
Sex Transm Infect. 2009 Dec;85(7):527-30
pubmed: 19584061
J Urol. 2004 Nov;172(5 Pt 1):1835-9
pubmed: 15540733
Can J Urol. 2003 Jun;10(3):1891-8
pubmed: 12892576
Urology. 2010 Sep;76(3):620-3
pubmed: 20599256
Urol Oncol. 2012 May-Jun;30(3):266-72
pubmed: 20869888
Cancer. 2019 Jun 15;125(12):2011-2017
pubmed: 30840335
J Natl Cancer Inst. 2010 Jun 2;102(11):802-11
pubmed: 20400716
Urology. 2002 Jun;59(6):923-9
pubmed: 12031382
Eur Urol. 2020 Jul;78(1):11-15
pubmed: 32307215
J Urol. 2014 Sep;192(3):659-64
pubmed: 24641909
J Urol. 2017 Sep;198(3):520-529
pubmed: 28479239
Urol Clin North Am. 2007 May;34(2):109-17; abstract vii
pubmed: 17484916
Urol Oncol. 2016 May;34(5):239.e1-8
pubmed: 26795607

Auteurs

Andrew B Katims (AB)

Department of Urology, Division of Urologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

Shirin Razdan (S)

Department of Urology, Division of Urologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

Benjamin M Eilender (BM)

Department of Urology, Division of Urologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

Peter Wiklund (P)

Department of Urology, Division of Urologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

Ashutosh K Tewari (AK)

Department of Urology, Division of Urologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

Natasha Kyprianou (N)

Department of Urology, Division of Urologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

Ketan K Badani (KK)

Department of Urology, Division of Urologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

Reza Mehrazin (R)

Department of Urology, Division of Urologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: reza.mehrazin@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH